1. Search Result
Search Result
Results for "

CD8/CD4 ratio

" in MedChemExpress (MCE) Product Catalog:

681

Inhibitors & Agonists

2

Screening Libraries

31

Fluorescent Dyes

20

Biochemical Assay Reagents

88

Peptides

10

MCE Kits

121

Inhibitory Antibodies

60

Natural
Products

39

Recombinant Proteins

22

Isotope-Labeled Compounds

19

Antibodies

3

Click Chemistry

43

Oligonucleotides

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9997

    ANB030

    PD-1/PD-L1 Inflammation/Immunology
    Rosnilimab (ANB030) is a PD-1 agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high PD-1 expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .
    Rosnilimab
  • HY-148808

    RXC007

    ROCK Cancer
    Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma [4].
    Zelasudil
  • HY-150741
    ODN 2216
    1 Publications Verification

    Toll-like Receptor (TLR) IFNAR Interleukin Related Infection Inflammation/Immunology Cancer
    ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
    ODN 2216
  • HY-P99908

    NT-17

    Interleukin Related Cancer
    Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4 + and CD8 + cells in both human and mice. Efineptakin alfa can be used for glioblastoma research .
    Efineptakin alfa
  • HY-P990792

    Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD4 Antibody (GK1.5) is an anti-mouse CD4 IgG2b monoclonal antibody. Anti-Mouse CD4 Antibody (GK1.5) can significantly deplete CD4 + T cells. Anti-Mouse CD4 Antibody (GK1.5) can extend the survival rate of xenograft models. Anti-Mouse CD4 Antibody (GK1.5) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682) .
    Anti-Mouse CD4 Antibody (GK1.5)
  • HY-P990855

    Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Anti-CD8α Antibody (OKT-8) is an anti-human CD8α IgG2a monoclonal antibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8 + T cells. Anti-CD8α Antibody (OKT-8) can be used for researches on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
    Anti-CD8α Antibody (OKT-8)
  • HY-150741C
    ODN 2216 sodium
    1 Publications Verification

    Toll-like Receptor (TLR) Cancer
    ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 sodium interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .
    ODN 2216 sodium
  • HY-134809

    CADA

    HIV Infection Inflammation/Immunology
    Cyclotriazadisulfonamide (CADA) is a specific CD4-targeted HIV entry inhibitors. Cyclotriazadisulfonamide (CADA) inhibits the co-translational translocation of human CD4 (huCD4) into the ER lumen in a signal peptide (SP)-dependent way. Cyclotriazadisulfonamide is also a Sec61 translocon inhibitor .
    Cyclotriazadisulfonamide
  • HY-P99834

    IAB22M2C; ImaginAb

    Transmembrane Glycoprotein Cancer
    Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research .
    Crefmirlimab
  • HY-P99128

    Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD8 beta Antibody (53-5.8) is an anti-mouse CD8 beta IgG2a monoclonal antibody. Anti-Mouse CD8 beta Antibody (53-5.8) can deplete CD8 + T cells and enhance cytotoxicity. Anti-Mouse CD8 beta Antibody (53-5.8) can be used for research on immunology .
    Anti-Mouse CD8 beta Antibody (53-5.8)
  • HY-P990790

    Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD8α Antibody (2.43) is an anti-mouse CD8α IgG2b monoclonal antibody. Anti-Mouse CD8α Antibody (2.43) can significantly deplete CD8 + T cells. Anti-Mouse CD8α Antibody (2.43) can prolong the survival time of liver cell transplantation. Anti-Mouse CD8α Antibody (2.43) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD8α Antibody (2.43): Rat IgG2b kappa, Isotype Control (HY-P990682) .
    Anti-Mouse CD8α Antibody (2.43)
  • HY-P990254

    CXCR Inflammation/Immunology Cancer
    Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse CXCR3/CD183 IgG monoclonal antibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4 + and CD8 + T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer .
    Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173)
  • HY-P99129
    Anti-Mouse CD8a Antibody (53-6.7)
    3 Publications Verification

    Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD8a Antibody (53-6.7) is an anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat. Anti-Mouse CD8a Antibody (53-6.7) binds to CD8αβ stabilizes a conformation with a higher affinity for interaction with MHC class I. Anti-Mouse CD8a Antibody (53-6.7) induces the phosphorylation and activation of TCR proximal signaling pathway components Lck and ZAP70 in polyclonal memory T cells. Anti-Mouse CD8a Antibody (53-6.7) depletes CD8+ T cells and neutralizes cytokine in mice .
    Anti-Mouse CD8a Antibody (53-6.7)
  • HY-P99159

    Interleukin Related Cancer
    Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4 + and CD8 + T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc .
    Ivuxolimab
  • HY-P2511

    Transmembrane Glycoprotein Metabolic Disease
    Insulin β Chain Peptide (15-23) is one of the earliest antigenic epitopes to which CD8 T-cells respond .
    Insulin β Chain Peptide (15-23)
  • HY-P11303

    CD74 MHC Neurological Disease Cancer
    PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4 + T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8 + T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer .
    PADRE peptide
  • HY-B0426A

    ALO4943A; KW4679

    Histamine Receptor CXCR Infection Neurological Disease Metabolic Disease Inflammation/Immunology
    Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine hydrochloride
  • HY-P2560
    LCMV GP (61-80)
    1 Publications Verification

    Arenavirus Infection Inflammation/Immunology
    LCMV GP (61-80) is a peptide fragment derived from lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP), and corresponds to amino acids 61-80. LCMV GP (61-80) is a specific epitope which can induce CD4 + T-cell response .
    LCMV GP (61-80)
  • HY-P991336

    INBRX-106; ES-102

    Orexin Receptor (OX Receptor) Inflammation/Immunology Cancer
    Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4 + and CD8 + T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer .
    Ordastobart
  • HY-P99266

    Anti-Human CD4 Recombinant Antibody

    Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .
    Zanolimumab
  • HY-P0272

    HIV Infection
    Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.
    Peptide T
  • HY-P990135

    Transmembrane Glycoprotein Infection Inflammation/Immunology
    Anti-Rat CD4 Antibody (OX-38) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to rat CD4. Anti-Rat CD4 Antibody (OX-38) can deplete CD4 + cells. Anti-Rat CD4 Antibody (OX-38) can be used for the researches of immunology and infection, such as borna disease and transplantation [4].
    Anti-Rat CD4 Antibody (OX-38)
  • HY-14134
    BMS-378806
    5+ Cited Publications

    BMS-806

    HIV Infection
    BMS-378806 is a potent HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. BMS-378806 selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.
    BMS-378806
  • HY-P990262

    Transmembrane Glycoprotein Metabolic Disease Inflammation/Immunology Cancer
    Anti-Mouse CD8 Antibody (HB-129) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD8. Anti-Mouse CD8 Antibody (HB-129) can deplete CD8 + T cells. Anti-Mouse CD8 Antibody (HB-129) can be used for the researches of cancer, inflammation, immunology and metabolic disease, such as P815 tumor, experimental autoimmune thyroiditis (EAT) and graft versus host disease (GVHD) .
    Anti-Mouse CD8 Antibody (HB-129)
  • HY-W062109

    Histamine Receptor CXCR Inflammation/Immunology
    Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine
  • HY-144088
    ZYF0033
    2 Publications Verification

    HPK1-IN-22

    MAP4K Inflammation/Immunology Cancer
    ZYF0033 is an orally active inhibitor of the hematopoietic progenitor cell kinase HPK1 with an IC50 of less than 10 nM based on the phosphorylation inhibition of MBP protein. ZYF0033 promotes anti-cancer immune responses and reduces phosphorylation of SLP76 (serine 376). ZYF0033 inhibits tumor growth in the 4T-1 syngeneic mouse model and leads to increased intratumoral infiltration of DCs, NK cells, and CD107a +CD8 + T cells, but not T cells, PD-1 +CD8 + T cells, TIM-3 +CD8 + Infiltration of T cells and LAG3 +CD8 + T cells was reduced .
    ZYF0033
  • HY-P9998

    UB421

    HIV Cancer
    Semzuvolimab is a human IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Human CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection .
    Semzuvolimab
  • HY-76648

    HIV Infection
    NBD-556, a CD4 mimetic, is a potent HIV-1 entry inhibitor that blocks the gp120-CD4 interaction. NBD-556 shows potent cell fusion and virus-cell fusion inhibitory activity at low micromolar levels .
    NBD-556
  • HY-162133

    STING Apoptosis IKK IFNAR NF-κB Cancer
    MSA-2-Pt, platinum salt-modified MSA-2 (HY-136927), is a STING agonist. MSA-2-Pt inducing cell
    death by platinum and activating the STING pathway by MSA-2. MSA-2-Pt direct activates STING pathway, induces phosphorylation of TBK1, IRF3, and NF-κB p65. MSA-2-Pt enhances tumor infiltration of CD4 + and CD8 + T cells, and induces tumor cell death and apoptosis in mouse colon carcinoma and melanoma models .
    MSA-2-Pt
  • HY-P5425A

    Transmembrane Glycoprotein Cancer
    Tetanus Toxin (830–844) TFA is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4 + T-cell epitope. This promiscuous CD4 + T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4 + T-cell responses in a large part of the human population) .
    Tetanus Toxin (830–844) TFA
  • HY-P5453

    CD3 Others
    CFP10 (71–85) is a biological active peptide. (CFP1071–85, that elicited IFN-γ production and CTL activity by both CD4+ and CD8+ T cells from persons expressing multiple MHC class II and class I molecules)
    CFP10 (71–85)
  • HY-P991246

    Virus Protease HIV Infection
    VRC01LS is a humanized monoclonal antibody inhibitor targeting the CD4-binding site of HIV-1 envelope glycoprotein (Env). VRC01LS blocks the binding of HIV-1 to host cell CD4 receptor, inhibiting viral entry. VRC01LS is promising for research of HIV-1 infection .
    VRC01LS
  • HY-P990242

    Galectin TNF Receptor IFNAR Interleukin Related Inflammation/Immunology Cancer
    Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4 + and CD8 + T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia [4].
    Anti-Mouse Galectin-9 Antibody (RG9-1)
  • HY-P990861

    Transmembrane Glycoprotein Infection Inflammation/Immunology Cancer
    Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human CD4. Anti-CD4 Antibody (OKT-4) can deplete T cells. Anti-CD4 Antibody (OKT-4) can be used for the researches of cancer, infection and immunology, such as melanoma and adenovirus infection .
    Anti-CD4 Antibody (OKT-4)
  • HY-P99999
    Anti-Mouse CD4 Antibody (YTS 191)
    1 Publications Verification

    HIV Infection
    Anti-Mouse CD4 Antibody (YTS 191) is anti-mouse CD4 IgG2b antibody inhibitor derived from host Rat.
    Anti-Mouse CD4 Antibody (YTS 191)
  • HY-P990264

    Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD70 Antibody (FR70) is a rat-derived ant-mouse CD70 IgG2b κ type antibody inhibitor. Anti-Mouse CD70 Antibody (FR70) decreases CD4 +, CD8 + T cells and eosinophils. Anti-Mouse CD70 Antibody (FR70) shows potent anti-inflammatory and anti-immune effects on allergic lung inflammation and cardiac transplant mice models .
    Anti-Mouse CD70 Antibody (FR70)
  • HY-P99028

    TMB-355; TNX-355

    HIV Infection
    Ibalizumab (TMB-355) is a humanized anti-CD4 IgG4 monoclonal antibody. Ibalizumab prevents HIV cell entry by binding to CD4 receptor. Ibalizumab can be used for the research of infection, such as HIV-1 infection .
    Ibalizumab
  • HY-P991112

    Transmembrane Glycoprotein Infection
    Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonal antibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8 + T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is applicable to research related to hepatitis B virus infection . Recommended isotype control: Rat IgG2b kappa, Isotype Control (HY-P990682).
    Anti-Mouse CD8α Antibody (YTS169.4)
  • HY-P99790

    CEN 000029; cM-T412

    Transmembrane Glycoprotein Inflammation/Immunology
    Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
    Priliximab
  • HY-P991402

    TNF Receptor Cancer
    BI-1910 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BI-1910 enhances T cell activation and induces CD8 T cell-dependent anti-tumor effects. BI-1910 can be used in solid tumors research. Recommended isotype control: Human IgG2 lambda, Isotype Control (HY-P991206) .
    BI-1910
  • HY-P99680

    SB-210396; IDEC CE9.1

    Interleukin Related Cancer
    Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
    Keliximab
  • HY-P5966

    MOG (40-54)

    MHC Inflammation/Immunology
    Myelin Oligodendrocyte Glycoprotein (40-54), Rat, Mouse (MOG (40-54)) is a CD8-related self-antigenic epitope of the myelin oligodendrocyte glycoprotein (MOG) protein and is presented in association with H-2Db .
    Myelin Oligodendrocyte Glycoprotein (40-54), Rat, Mouse
  • HY-P990126

    Transmembrane Glycoprotein Infection Inflammation/Immunology
    Anti-Rat CD8α Antibody (OX-8) is an anti-rat CD8α IgG1 monoclonal antibody. Anti-Rat CD8α Antibody (OX-8) can deplete CD8 + T cells. Anti-Rat CD8α Antibody (OX-8) can enhance airway remodeling. Anti-Rat CD8α Antibody (OX-8) can be used for researches on allergic conditions and infections such as RHV-rn1 virus infection and asthma .
    Anti-Rat CD8α Antibody (OX-8)
  • HY-P990304

    TNF Receptor Infection Inflammation/Immunology Cancer
    Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) is a rat-derived IgG2a κ antibody inhibitor, targeting to mouse 4-1BBL/CD137L. Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) can block 4-1BB ligand (4-1BBL) and inhibit CD4 + and CD8 + T cells. Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) can be used for the researches of cancer, infection, inflammation and immunology, such as MC38 tumor, lymphocytic choriomeningitis virus (LCMV) infection and herpetic stromal keratitis (HSK) [4] .
    Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1)
  • HY-P99607

    IDEC-151

    HIV Inflammation/Immunology
    Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
    Clenoliximab
  • HY-P4015

    HIV Neurological Disease Metabolic Disease
    VIP (1-12), human, porcine, rat, ovine is a vasoactive intestinal peptide (VIP) fragment. VIP (1-12), human, porcine, rat, ovine is a ligand for the CD4 (T4)/human immunodeficiency virus receptor .
    VIP (1-12), human, porcine, rat, ovine
  • HY-W062109S

    Isotope-Labeled Compounds Histamine Receptor CXCR Inflammation/Immunology
    Olopatadine-d6 is the deuterium labeled Olopatadine. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine-d6
  • HY-P991655

    IFNAR HIV Infection Inflammation/Immunology
    AGS-009 is a humanized monoclonal neutralising antibody targeting IFN-α. AGS-009 significantly reduces activated lymphocytes, such as CD4 + and CD8 + T cells as well as B cells in SIV infection rhesus macaque models. AGS-009 can be used for autoimmune diseases like systemic lupus erythematosus (SLE) and HIV infections research .
    AGS-009
  • HY-P10593

    Transmembrane Glycoprotein Influenza Virus Cancer
    Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .
    Influenza A NP (383-391) (HLA-B27)
  • HY-W060417

    Interleukin Related Inflammation/Immunology Cancer
    iST2-1 is an Stimulation-2 (ST2) inhibitor with an IC50 value of 46.65 μM, blocks interaction between ST2 and IL-33, inhibits downstream signaling. iST2-1 functions as an immunomodulator, reduces proliferation of CD4 + and CD8 + T cells, increases regulatory T cell populations, reduces IFN-γ +CD4 + T cell populations, increases Foxp3 +CD4 + regulatory T cell populations in the gastrointestinal tract. iST2-1 reduces plasma soluble ST2 and IFN-γ levels, reduces graft-versus-host disease scores, improves survival in graft-versus-host disease animal models, preserves graft-versus-tumor effect. iST2-1 can be used for the research of graft-versus-host disease .
    iST2-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: